BIOLINERX
RSS
RSS
| Careers | Contact Us
search

Investor relations home

BioLineRx is a clinical-stage, publicly-traded (NASDAQ/ TASE: BLRX) biopharmaceutical development company based in Jerusalem, Israel.
The Company develops products suitable for the pharmaceutical market satisfying an unmet medical need or exhibiting advantages over current therapies.

BioLineRx's close ties with universities, research institutes, academic institutions, technology transfer offices and biotech... More >>

Therapeutic pipeline
Title
Download Documentation Pipeline
Upcoming events
DateTitle
09/30/14
BioLineRx will present at the 14th Annual Biotech in Europe Forum for Global Partnering & Investment at the Congress Center in Basel, Switzerland on September 30 - October 1, 2014
10/08/14
through
10/12/14
BioLineRx will present BL-5010 program (a novel formulation for the non-surgical removal of benign and pre-cancerous skin lesions) at the 23rd EADV Congress in Amsterdam, the Netherlands on October 8-12, 2014
10/09/14
BioLineRx to present BL-1110 (an orally-administered small molecule designed to interfere with the binding of morphine to the toll-like receptor-4 (TLR-4) on glial cells) at the IASP 15th World Congress on Pain on Oct. 9, 2014 at 9:30 am in Buenos Aires
10/18/14
through
10/22/14
BioLineRx will present BL-7040 program (an orally available oligonucleotide for the treatment of inflammatory bowel disease) at the UEG Week 2014, October 18-22, 2014 in Vienna, Austria
01/12/15
BioLineRx to attend the JP Morgan Financial 33rd Annual Healthcare Investor Conference in San Francisco, CA, to be held during week of January 12, 2015
What's new
DateTitle
09/01/14
Download Documentation BioLineRx Company presentation
08/27/14
Download Documentation BioLineRx AGM Proxy Statement
08/27/14
Download Documentation BioLineRx AGM Proxy Card
08/06/14
Download Documentation Second Quarter 2014 Earnings Presentation
Get help downloading or viewing the above file types